Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Authorizes Pfizer's Paxlovid, In The Nick Of Time

Dec 23 2021

• By Mary Jo Laffler

production line — Pfizer Is Ramping Production Up To 120 Million Doses By End Of 2022

Related Content

Pfizer Getting $529 Per Course For Paxlovid Under US Contract; Did Merck Drive A Harder Bargain?

Nov 19 2021

Divided US FDA AdComm Backs Molnupiravir Authorization But Wants More Studies

Dec 01 2021

Pfizer’s Bourla On Paxlovid Patent Deal And Why A Similar Approach Won't Work For Comirnaty

Nov 17 2021

Antibody Therapies Vs. Omicron: Vir Stands Up But Regeneron And Lilly Fail

Dec 17 2021

Pfizer Confirms Paxlovid’s High Efficacy And Reassures On Omicron

Dec 15 2021

Related Companies

Pfizer Inc.

Merck & Co., Inc.

Ridgeback Biotherapeutics LP

BioNTech SE

Arena Pharmaceuticals, Inc.

Additional Topics

Coronavirus COVID-19 Launches Approvals Companies Commercial Infectious Diseases BioPharmaceutical

More from COVID-19

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window